The state Supreme Court is considering how far a pharmaceutical company need go in warning consumers about the possible side effects of their drugs in order to be shielded from suit under the Products Liability Act.

Paul Schmidt, a lawyer representing Hoffmann-La Roche Inc. told the Court on Monday that a PLA suit by a woman who developed inflammatory bowel disease after using the acne drug Accutane should have been time-barred, due to the statute’s presumption that warnings approved by the Food and Drug Administration provide adequate notice of the risks.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]